NextCure disclosed on January 13, 2020 that Eli Lilly and Company had ended its collaboration agreement for the research and development of NC318, NextCure’s leading product candidate, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor, particularly for patients with advanced or metastatic solid tumors.
On January 13, 2020, NextCure’s share price fell $4.70, or 8%, on this news, to close at $52.00 per share, injuring investors.
Then, on July 13, 2020, before the market opened, NextCure announced that it was no longer planning to “advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial.” NextCure announced the resignation of its Chief Medical Officer on the same day.
On July 13, 2020, NextCure’s share price fell $9.73, or 54%, on this news to close at $8.15 per share, injuring investors further.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067